Dalteparin, darbepoetin, dasatinib, dexamethasone + neomycin sulphate + polymyxin B sulfate, epoetin beta, epoetin theta, epoetin zeta, erlotinib, estradiol + cyproterone, etoricoxib, everolimus, follitropin beta, formoterol + beclomethasone, fusidic + betamethasone, fusidic + hydrocortisone , goserelin, hydromorphone hydrochloride, ketorolac, levothyroxine + liothyronine, Linezolid, nadroparin, paliperidone palmitate, pazopanib, pegfilgrastim, piribedil, progesterone, prothipendyl, Reviparin
, risperidone, sildenafil, sumatriptan, tinzaparin, tobramycin, tobramycin + dexamethasone, voriconazole.
Lastly, Wirth and coworkers (9) randomized 262 patients undergoing elective knee arthroscopy to receive either no treatment or reviparin
once daily subcutaneously for 7 to 10 days.
20] evaluated a total of 1137 patients with DVT who were randomly assigned to UFH or reviparin
for 5-7 days.
NEW ORLEANS -- Antithrombotic treatment, in the form of the low-molecular-weight heparin reviparin, has been shown for the first time to safely improve outcomes after acute myocardial infarction.
Reviparin "clearly improves the outcomes of patients who undergo thrombolysis with streptokinase or urokinase, and it also appears to be a useful adjunct for patients treated with primary percutaneous coronary intervention [PCI]," said Dr.
But the value of adding reviparin or a similar agent remains in doubt when patients are treated with the fibrin-specific drugs typically used for thrombolysis in the United States, such as alteplase (tissue plasminogen activator), reteplase, and tenecteplase.
Abbott provided the reviparin for the study, which had no other commercial funding.
Patients were randomized to reviparin or placebo by subcutaneous injection b.
The protective effect of reviparin treatment extended to 30 days after treatment began.
The use of the low-molecular-weight heparins (LMWHs) dalteparin, enoxaparin, nadroparin, reviparin
, and tinzaparin resulted in only one vertebral fracture in 486 pregnancies at 21 centers in one study reviewed.
Participants were assigned to one of three treatment regimens: intravenous administration of unfractionated heparin; subcutaneous administration of a low-molecular-weight heparin, reviparin
, twice a day for 1 week; or subcutaneous administration of reviparin
once a day for 4 weeks.
LMWH preparations evaluated were certoparin, dalteparin, enoxaparin, nadroparin, reviparin
, and tinzaparin.